Symbols / PASG Stock $5.36 -2.90% Passage Bio, Inc.

Healthcare • Biotechnology • United States • NCM
PASG (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. William Chou M.D.
Exch · Country NCM · United States
Market Cap 17.19M
Enterprise Value -10.39M
Income -37.68M
Sales —
FCF (ttm) -13.15M
Book/sh 5.89
Cash/sh 10.39
Employees 24
Insider 10d —
IPO Feb 28, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.70
PEG —
P/S —
P/B 0.91
P/C —
EV/EBITDA 0.28
EV/Sales —
Quick Ratio 1.66
Current Ratio 1.73
Debt/Eq 48.97
LT Debt/Eq —
EPS (ttm) -11.84
EPS next Y -7.68
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-03
Earnings (prior) 2026-03-03
ROA -38.35%
ROE -128.90%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 3.21M
Shs Float 2.89M
Insider Own 0.41%
Instit Own 52.82%
Short Float 5.64%
Short Ratio 1.16
Short Interest 145.03K
52W High 20.00
vs 52W High -73.20%
52W Low 3.94
vs 52W Low 36.21%
Beta —
Impl. Vol. —
Rel Volume 0.53
Avg Volume 78.40K
Volume 41.19K
Target (mean) $11.40
Tgt Median $9.00
Tgt Low $7.00
Tgt High $23.00
# Analysts 5
Recom None
Prev Close $5.52
Price $5.36
Change -2.90%
About

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$11.40
Mean price target
2. Current target
$5.36
Latest analyst target
3. DCF / Fair value
$-73.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.36
Low
$7.00
High
$23.00
Mean
$11.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-21 down TD Cowen Buy → Hold —
2026-04-21 down Chardan Capital Buy → Neutral $7
2026-04-21 main Oppenheimer Outperform → Outperform $15
2026-04-21 down Wedbush Outperform → Neutral $8
2026-03-31 init Oppenheimer — → Outperform $30
2026-03-04 main Canaccord Genuity Buy → Buy $23
2025-11-12 main Chardan Capital Buy → Buy $21
2025-08-14 main Canaccord Genuity Buy → Buy $67
2025-08-14 main Guggenheim Buy → Buy $10
2025-08-13 main Wedbush Outperform → Outperform $40
2025-06-24 main Chardan Capital Buy → Buy $6
2025-03-04 main Chardan Capital Buy → Buy $6
2024-11-14 main Chardan Capital Buy → Buy $7
2024-11-14 main Canaccord Genuity Buy → Buy $13
2024-09-17 reit Canaccord Genuity Buy → Buy $13
2024-09-03 init Rodman & Renshaw — → Buy $7
2024-05-15 main Canaccord Genuity Buy → Buy $13
2024-03-05 reit Canaccord Genuity Buy → Buy $14
2023-11-14 main Raymond James Outperform → Outperform $5
2023-08-08 main Chardan Capital Buy → Buy $9
News
RSS: Latest PASG news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-08 CHOU WILLIAM Chief Executive Officer — 10,000 — —
2026-01-08 BORTHWICK KATHLEEN Chief Financial Officer — 5,000 — —
2026-01-08 CHOU WILLIAM Chief Executive Officer — 4,076 $18.44 $75,159
2026-01-08 BORTHWICK KATHLEEN Chief Financial Officer — 2,062 $18.44 $38,022
2025-09-15 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 32,008 $6.96 $223,735
2025-07-24 LYNX1 CAPITAL MANAGEMENT LP Beneficial Owner of more than 10% of a Class of Security — 128,848 $5.44 $733,826
2025-06-26 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 583,657 $0.33 $197,239
2025-04-24 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 235,572 $0.32 $78,731
2025-04-17 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 149,054 $0.33 $49,704
2025-02-11 BORTHWICK KATHLEEN Chief Financial Officer — 3,183 $0.53 $1,686
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
43.15
-33.78%
65.17
-36.73%
103.00
-23.93%
135.39
Research And Development
23.28
-42.07%
40.18
-34.58%
61.42
-28.63%
86.05
Selling General And Administration
19.88
-20.46%
24.99
-39.90%
41.58
-15.73%
49.34
General And Administrative Expense
19.88
-20.46%
24.99
-39.90%
41.58
-15.73%
49.34
Other Gand A
19.88
-20.46%
24.99
-39.90%
41.58
-15.73%
49.34
Total Expenses
43.15
-33.78%
65.17
-36.73%
103.00
-23.93%
135.39
Operating Income
-43.15
+33.78%
-65.17
+36.73%
-103.00
+23.93%
-135.39
Total Operating Income As Reported
-49.30
+29.98%
-70.40
+35.05%
-108.39
+21.68%
-138.39
EBITDA
-42.42
+31.67%
-62.09
+37.46%
-99.28
+24.63%
-131.72
Normalized EBITDA
-36.28
+36.19%
-56.85
+39.45%
-93.89
+27.06%
-128.72
Reconciled Depreciation
0.73
-76.37%
3.08
-17.20%
3.72
+1.14%
3.68
EBIT
-43.15
+33.78%
-65.17
+36.73%
-103.00
+23.93%
-135.39
Total Unusual Items
-6.14
-17.43%
-5.23
+2.91%
-5.39
-79.67%
-3.00
Total Unusual Items Excluding Goodwill
-6.14
-17.43%
-5.23
+2.91%
-5.39
-79.67%
-3.00
Special Income Charges
-6.14
-17.43%
-5.23
+2.91%
-5.39
-79.67%
-3.00
Other Special Charges
—
—
—
3.00
Impairment Of Capital Assets
6.14
+17.43%
5.23
-2.91%
5.39
0.00
Write Off
—
5.23
-2.91%
5.39
0.00
Net Income
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Pretax Income
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Net Non Operating Interest Income Expense
—
—
—
2.27
Net Interest Income
—
—
—
2.27
Interest Income Non Operating
—
—
—
2.27
Interest Income
—
—
—
2.27
Other Income Expense
-2.37
-692.75%
0.40
-57.31%
0.94
+228.18%
-0.73
Other Non Operating Income Expenses
3.77
-33.00%
5.63
-10.97%
6.33
+178.85%
2.27
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Net Income From Continuing Operation Net Minority Interest
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Net Income From Continuing And Discontinued Operation
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Net Income Continuous Operations
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Normalized Income
-39.38
+33.86%
-59.53
+38.42%
-96.67
+27.38%
-133.12
Net Income Common Stockholders
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Diluted EPS
—
-21.40
+42.47%
-37.20
+25.60%
-50.00
Basic EPS
—
-21.40
+42.47%
-37.20
+25.60%
-50.00
Basic Average Shares
—
3.02
+10.34%
2.74
+0.58%
2.72
Diluted Average Shares
—
3.02
+10.34%
2.74
+0.58%
2.72
Diluted NI Availto Com Stockholders
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
62.28
-39.19%
102.41
-31.97%
150.54
-38.19%
243.55
Current Assets
47.76
-39.40%
78.81
-33.18%
117.96
-40.14%
197.04
Cash Cash Equivalents And Short Term Investments
46.30
-39.68%
76.76
-32.84%
114.29
-39.72%
189.61
Cash And Cash Equivalents
46.30
+23.23%
37.57
+73.08%
21.71
-37.26%
34.60
Cash Equivalents
43.80
+28.66%
34.05
+87.96%
18.11
-33.09%
27.07
Cash Financial
2.50
-29.12%
3.53
-1.92%
3.60
-52.26%
7.53
Other Short Term Investments
0.00
-100.00%
39.18
-57.68%
92.58
-40.27%
155.01
Prepaid Assets
0.83
-32.02%
1.22
-55.47%
2.74
-57.87%
6.51
Other Current Assets
0.63
-24.94%
0.84
-9.21%
0.92
-0.32%
0.93
Total Non Current Assets
14.52
-38.47%
23.60
-27.59%
32.59
-29.93%
46.51
Net PPE
14.28
-38.29%
23.13
-28.05%
32.15
-23.88%
42.24
Gross PPE
18.19
-44.63%
32.86
-16.58%
39.39
-16.89%
47.39
Accumulated Depreciation
-3.92
+59.72%
-9.72
-34.38%
-7.24
-40.42%
-5.15
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.51
-8.19%
1.65
+2.11%
1.61
-44.29%
2.90
Construction In Progress
—
0.00
-100.00%
0.64
-50.58%
1.29
Other Properties
10.17
-57.32%
23.82
-11.51%
26.92
-9.33%
29.70
Leases
6.51
-11.86%
7.39
-27.68%
10.21
-24.38%
13.51
Other Non Current Assets
0.24
-47.30%
0.46
+6.93%
0.43
-89.85%
4.27
Total Liabilities Net Minority Interest
43.53
+5.77%
41.15
+4.81%
39.26
-6.92%
42.18
Current Liabilities
23.08
+19.21%
19.36
+18.49%
16.34
-10.95%
18.35
Payables And Accrued Expenses
3.03
-0.59%
3.04
-51.93%
6.33
-4.49%
6.63
Payables
2.04
+174.53%
0.74
-77.50%
3.30
-18.87%
4.07
Accounts Payable
1.11
+50.00%
0.74
-42.84%
1.30
-68.07%
4.07
Current Accrued Expenses
0.99
-57.04%
2.30
-24.13%
3.03
+18.28%
2.56
Pensionand Other Post Retirement Benefit Plans Current
2.74
-37.80%
4.41
-33.62%
6.64
-21.43%
8.45
Current Debt And Capital Lease Obligation
3.57
-3.28%
3.69
+9.34%
3.37
+2.99%
3.27
Current Capital Lease Obligation
3.57
-3.28%
3.69
+9.34%
3.37
+2.99%
3.27
Current Deferred Liabilities
13.75
+67.15%
8.23
0.00
—
Current Deferred Revenue
13.75
+67.15%
8.23
0.00
—
Total Non Current Liabilities Net Minority Interest
20.44
-6.17%
21.79
-4.94%
22.92
-3.82%
23.83
Long Term Debt And Capital Lease Obligation
20.44
-6.17%
21.79
-4.94%
22.92
-3.82%
23.83
Long Term Capital Lease Obligation
20.44
-6.17%
21.79
-4.94%
22.92
-3.82%
23.83
Non Current Deferred Liabilities
—
—
—
0.00
Stockholders Equity
18.75
-69.39%
61.26
-44.95%
111.28
-44.74%
201.37
Common Stock Equity
18.75
-69.39%
61.26
-44.95%
111.28
-44.74%
201.37
Capital Stock
0.00
0.00
-100.00%
0.01
+0.00%
0.01
Common Stock
0.00
0.00
-100.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
3.18
+2.57%
3.10
+12.95%
2.75
+0.60%
2.73
Ordinary Shares Number
3.18
+2.57%
3.10
+12.95%
2.75
+0.60%
2.73
Additional Paid In Capital
723.51
+0.42%
720.49
+2.08%
705.79
+1.59%
694.73
Retained Earnings
-704.76
-6.91%
-659.24
-10.89%
-594.47
-20.73%
-492.41
Gains Losses Not Affecting Retained Earnings
0.00
-100.00%
0.01
+118.60%
-0.04
+95.55%
-0.97
Other Equity Adjustments
—
0.01
+118.60%
-0.04
+95.55%
-0.97
Total Equity Gross Minority Interest
18.75
-69.39%
61.26
-44.95%
111.28
-44.74%
201.37
Total Capitalization
18.75
-69.39%
61.26
-44.95%
111.28
-44.74%
201.37
Working Capital
24.68
-58.49%
59.45
-41.49%
101.62
-43.13%
178.69
Invested Capital
18.75
-69.39%
61.26
-44.95%
111.28
-44.74%
201.37
Total Debt
24.01
-5.75%
25.48
-3.11%
26.29
-3.00%
27.11
Capital Lease Obligations
24.01
-5.75%
25.48
-3.11%
26.29
-3.00%
27.11
Net Tangible Assets
18.75
-69.39%
61.26
-44.95%
111.28
-44.74%
201.37
Tangible Book Value
18.75
-69.39%
61.26
-44.95%
111.28
-44.74%
201.37
Dueto Related Parties Current
0.92
0.00
-100.00%
2.00
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-31.51
+34.30%
-47.96
+38.73%
-78.26
+33.79%
-118.21
Cash Flow From Continuing Operating Activities
-31.51
+34.30%
-47.96
+38.73%
-78.26
+33.79%
-118.21
Net Income From Continuing Operations
-45.52
+29.71%
-64.77
+36.54%
-102.06
+25.02%
-136.12
Depreciation Amortization Depletion
0.73
-76.37%
3.08
-17.20%
3.72
+1.14%
3.68
Depreciation And Amortization
0.73
-76.37%
3.08
-17.20%
3.72
+1.14%
3.68
Other Non Cash Items
0.01
—
—
3.00
Stock Based Compensation
3.00
-48.44%
5.82
-46.71%
10.92
-42.38%
18.95
Asset Impairment Charge
6.14
+17.43%
5.23
-2.91%
5.39
0.00
Operating Gains Losses
—
—
0.46
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.46
0.00
Change In Working Capital
4.00
-4.95%
4.20
-21.26%
5.34
+162.88%
-8.49
Change In Prepaid Assets
0.62
-65.15%
1.78
-76.64%
7.60
+100.29%
3.80
Change In Payables And Accrued Expense
-0.17
+96.85%
-5.52
-158.99%
-2.13
+83.29%
-12.75
Change In Accrued Expense
-2.05
+58.61%
-4.96
-853.11%
0.66
+108.98%
-7.34
Change In Payable
1.88
+438.13%
-0.56
+80.07%
-2.79
+48.45%
-5.41
Change In Account Payable
1.88
+438.13%
-0.56
+80.07%
-2.79
+48.45%
-5.41
Change In Other Working Capital
3.55
-55.32%
7.95
+6075.19%
-0.13
-128.73%
0.46
Investing Cash Flow
40.22
-26.81%
54.95
-15.77%
65.24
+158.89%
25.20
Cash Flow From Continuing Investing Activities
40.22
-26.81%
54.95
-15.77%
65.24
+158.89%
25.20
Net PPE Purchase And Sale
1.17
+3541.18%
-0.03
+76.71%
-0.15
+93.58%
-2.27
Purchase Of PPE
0.00
+100.00%
-0.03
+76.71%
-0.15
+93.58%
-2.27
Sale Of PPE
1.17
0.00
—
—
Capital Expenditure
—
-0.03
+76.71%
-0.15
+97.23%
-5.27
Net Investment Purchase And Sale
39.05
-28.98%
54.98
-15.91%
65.38
+114.56%
30.47
Purchase Of Investment
0.00
+100.00%
-88.17
+31.88%
-129.43
+18.00%
-157.84
Sale Of Investment
39.05
-72.72%
143.15
-26.52%
194.81
+3.46%
188.31
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-3.00
Purchase Of Intangibles
—
—
0.00
+100.00%
-3.00
Financing Cash Flow
0.02
-99.74%
8.87
+6473.33%
0.14
+109.98%
-1.35
Cash Flow From Continuing Financing Activities
0.02
-99.74%
8.87
+6473.33%
0.14
+109.98%
-1.35
Net Common Stock Issuance
0.00
-100.00%
8.74
0.00
0.00
Proceeds From Stock Option Exercised
0.02
-82.58%
0.13
-2.22%
0.14
-68.82%
0.43
Net Other Financing Charges
—
—
—
-1.79
Changes In Cash
8.73
-44.97%
15.86
+223.05%
-12.89
+86.34%
-94.36
Beginning Cash Position
37.57
+73.08%
21.71
-37.26%
34.60
-73.17%
128.97
End Cash Position
46.30
+23.23%
37.57
+73.08%
21.71
-37.26%
34.60
Free Cash Flow
-31.51
+34.34%
-47.99
+38.80%
-78.41
+36.50%
-123.48
Amortization Of Securities
0.13
+108.45%
-1.53
+25.00%
-2.04
-363.39%
0.77
Common Stock Issuance
0.00
-100.00%
8.74
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
8.74
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category